Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now - TradingView

AI-generated analysis

📈 Cencora's U.S. Healthcare Solutions business showed accelerating momentum with fiscal third-quarter revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million.

🚀 OneOncology is emerging as a meaningful long-term growth platform, performing modestly above expectations with a three-phase value-creation plan progressing through integration and new services.

🌍 International Healthcare Solutions revenues increased 6% to $7.7 billion, while operating income rose 21%, driven by World Courier stabilization and European 3PL growth.

💉 GLP-1 demand is becoming a significant structural volume driver, with U.S. Healthcare Solutions recording a $2.3 billion year-over-year increase in sales.

📉 Manufacturer list-price reductions remain a major drag on headline revenue, creating a $2.4 billion headwind that offset the incremental GLP-1 sales in the fiscal third quarter.

⚠️ The pending divestiture of MWI Animal Health to Covetrus could create an approximately $150 million operating-income headwind within Other starting around fiscal 2027.

📊 Analyst consensus estimates for fiscal 2026 earnings have moved north to $17.79 per share, reflecting a stable improving revision trend over the past 30 days.

🔮 Management expects full-year U.S. revenue growth in the lower half of its 4-6% guided range as it laps prior oncology customer losses and benefits from easier expense comparisons.

⚖️ Regulatory uncertainty regarding proposed changes to 340B and ASP rules remains a persistent risk that could vary across Cencora's broad customer base.

💵 The company has a market capitalization of $64.19 billion and is one of the world's largest pharmaceutical service companies focused on drug distribution.

Bullish Signals
  • Cencora's U.S. Healthcare Solutions business showed accelerating underlying momentum with fiscal third-quarter revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million.
  • OneOncology is performing modestly above expectations and serves as a meaningful long-term growth platform for clinical trials and new services beyond initial distribution benefits.
  • International Healthcare Solutions revenues increased 6% to $7.7 billion while operating income rose 21%, providing a diversified earnings stream with double-digit growth from World Courier and European 3PL.
  • GLP-1 demand is becoming an important structural volume driver, with U.S. Healthcare Solutions recording a $2.3 billion year-over-year increase in sales broadly in line with expectations.
  • Cencora's specialty-centric model is well-positioned to benefit from pharmaceutical innovation, including biosimilars and complex therapies, particularly Part B biosimilars which offer favorable profit opportunities.
  • Analyst consensus estimates for fiscal 2026 earnings have improved, moving north 8 cents to $17.79 per share in the past 30 days, indicating a stable improving revision trend.
Risk Factors
  • Manufacturer list-price reductions remain a major drag on headline revenue growth, creating a $2.4 billion headwind in the fiscal third quarter that offset incremental GLP-1 sales.
  • The pending divestiture of MWI Animal Health to Covetrus is expected to create an approximately $150 million operating-income headwind within Other if it closes around the midpoint of fiscal 2027.
  • Regulatory and pricing uncertainty regarding proposed changes to 340B and ASP rules remains a persistent risk that could pressure Cencora's specialty and distribution economics.
Full Analysis
Cencora (COR) is a leading global pharmaceutical service company with a market capitalization of $64.19 billion, focusing on drug distribution and healthcare solutions to reduce costs and improve patient outcomes. The company's U.S. Healthcare Solutions business demonstrated accelerating momentum in the fiscal third quarter, with revenues rising 5% to $74.9 billion and operating income increasing 16% to $966 million, driven by strength in specialty segments. Key growth drivers include the OneOncology acquisition, which is performing above expectations and serving as a long-term platform for clinical trials and new services, alongside robust international operations where revenues grew 6% and operating income rose 21%. Additionally, Cencora is capitalizing on structural volume opportunities from GLP-1 demand, which saw a $2.3 billion year-over-year increase in sales, and the expanding market for Part B biosimilars. Despite positive underlying performance, Cencora faces headwinds including manufacturer list-price reductions that suppressed headline revenue growth by $2.4 billion in the quarter, offsetting the GLP-1 gains. The company also anticipates a potential earnings reset in fiscal 2027 due to the divestiture of its MWI Animal Health business to Covetrus, which is expected to create an approximate $150 million operating-income headwind. Regulatory uncertainty regarding 340B and ASP rules remains a persistent risk to specialty economics. Analyst consensus estimates for fiscal 2026 show improving trends, with earnings expectations revised north to $17.79 per share and revenue pegged at $88.09 billion, implying year-over-year growth of 5.2%. While the stock has underperformed the S&P 500 year-to-date, management expects full-year U.S. revenue growth in the lower half of its 4-6% guided range as it fully laps prior oncology customer losses and benefits from easier expense comparisons.